-
Je něco špatně v tomto záznamu ?
Associations of KLOTHO-VS heterozygosity and α-Klotho protein with cerebrospinal fluid Alzheimer's disease biomarkers
A. Katonova, R. Andel, V. Jurasova, K. Veverova, F. Angelucci, V. Matoska, J. Hort
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články
- MeSH
- Alzheimerova nemoc * mozkomíšní mok genetika MeSH
- amyloidní beta-protein mozkomíšní mok MeSH
- apolipoprotein E4 genetika MeSH
- biologické markery mozkomíšní mok MeSH
- glukuronidasa * genetika MeSH
- heterozygot MeSH
- kognitivní dysfunkce mozkomíšní mok genetika MeSH
- lidé středního věku MeSH
- lidé MeSH
- peptidové fragmenty mozkomíšní mok MeSH
- proteiny Klotho genetika MeSH
- proteiny tau mozkomíšní mok MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři nad 80 let MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
BackgroundKLOTHO-VS heterozygosity (KL-VSHET) and soluble α-Klotho (sαKl) protein interfere with Alzheimer's disease (AD) pathophysiology, but the specific relationships remain unclear. This study explored these associations across the AD continuum, focusing on core AD biomarkers and markers of neurodegeneration, neuroinflammation, and synaptic dysfunction.ObjectiveWe investigated whether 1) KL-VSHET is associated with lower AD biomarker burden (Aβ42, Aβ42/40 ratio, P-tau181, T-tau) and neurodegeneration (NfL); 2) sαKl relates to AD biomarkers, neurodegeneration (NfL), neuroinflammation (GFAP), and synaptic dysfunction (Ng); 3) associations vary by APOE ε4 status and clinical subgroup.MethodsParticipants (n = 223) were categorized as cognitively healthy (n = 38), aMCI-AD (n = 94), and AD dementia (n = 91). KLOTHO genotyping was available for 128 participants; 138 had cerebrospinal fluid (CSF) and serum sαKl measurements; and 42 had both. Multiple linear regression evaluated associations between KL-VSHET, sαKl levels, and biomarkers, stratified by APOE ε4 status and clinical subgroup.ResultsOverall, the associations between KL-VSHET and higher CSF Aβ42 and Aβ42/40 ratio were non-significant (ps ≥ 0.059) except when restricted to APOE ε4 carriers only (β = 0.11, p = 0.008 and β = 0.16, p = 0.033, respectively). Within clinical subgroups, KL-VSHET was positively associated with Aβ42/40 ratio only in aMCI-AD (β = 0.23, p = 0.034). No significant associations were observed between KL-VSHET and tau biomarkers or NfL. For sαKl, associations with biomarkers were non-significant except for a negative association of serum sαKl with P-tau181 in aMCI-AD (β = -0.25, p = 0.036) and a positive association with Aβ42/40 ratio in APOE ε4 non-carriers (β = 0.24 p = 0.047).ConclusionsKL-VSHET may help protect against amyloid pathology, particularly in the presence of APOE ε4, and regardless of APOE status in aMCI-AD.
Department of Clinical Biochemistry Hematology and Immunology Homolka Hospital Prague Czech Republic
Edson College of Nursing and Health Innovation Arizona State University Phoenix AZ USA
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25015907
- 003
- CZ-PrNML
- 005
- 20250731091340.0
- 007
- ta
- 008
- 250708s2025 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1177/13872877251326199 $2 doi
- 035 __
- $a (PubMed)40112321
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Katonova, Alzbeta $u Memory Clinic, Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic $1 https://orcid.org/0009000656057200
- 245 10
- $a Associations of KLOTHO-VS heterozygosity and α-Klotho protein with cerebrospinal fluid Alzheimer's disease biomarkers / $c A. Katonova, R. Andel, V. Jurasova, K. Veverova, F. Angelucci, V. Matoska, J. Hort
- 520 9_
- $a BackgroundKLOTHO-VS heterozygosity (KL-VSHET) and soluble α-Klotho (sαKl) protein interfere with Alzheimer's disease (AD) pathophysiology, but the specific relationships remain unclear. This study explored these associations across the AD continuum, focusing on core AD biomarkers and markers of neurodegeneration, neuroinflammation, and synaptic dysfunction.ObjectiveWe investigated whether 1) KL-VSHET is associated with lower AD biomarker burden (Aβ42, Aβ42/40 ratio, P-tau181, T-tau) and neurodegeneration (NfL); 2) sαKl relates to AD biomarkers, neurodegeneration (NfL), neuroinflammation (GFAP), and synaptic dysfunction (Ng); 3) associations vary by APOE ε4 status and clinical subgroup.MethodsParticipants (n = 223) were categorized as cognitively healthy (n = 38), aMCI-AD (n = 94), and AD dementia (n = 91). KLOTHO genotyping was available for 128 participants; 138 had cerebrospinal fluid (CSF) and serum sαKl measurements; and 42 had both. Multiple linear regression evaluated associations between KL-VSHET, sαKl levels, and biomarkers, stratified by APOE ε4 status and clinical subgroup.ResultsOverall, the associations between KL-VSHET and higher CSF Aβ42 and Aβ42/40 ratio were non-significant (ps ≥ 0.059) except when restricted to APOE ε4 carriers only (β = 0.11, p = 0.008 and β = 0.16, p = 0.033, respectively). Within clinical subgroups, KL-VSHET was positively associated with Aβ42/40 ratio only in aMCI-AD (β = 0.23, p = 0.034). No significant associations were observed between KL-VSHET and tau biomarkers or NfL. For sαKl, associations with biomarkers were non-significant except for a negative association of serum sαKl with P-tau181 in aMCI-AD (β = -0.25, p = 0.036) and a positive association with Aβ42/40 ratio in APOE ε4 non-carriers (β = 0.24 p = 0.047).ConclusionsKL-VSHET may help protect against amyloid pathology, particularly in the presence of APOE ε4, and regardless of APOE status in aMCI-AD.
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a Alzheimerova nemoc $x mozkomíšní mok $x genetika $7 D000544
- 650 _2
- $a proteiny Klotho $x genetika $7 D000090265
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a biologické markery $x mozkomíšní mok $7 D015415
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a amyloidní beta-protein $x mozkomíšní mok $7 D016229
- 650 _2
- $a proteiny tau $x mozkomíšní mok $7 D016875
- 650 _2
- $a heterozygot $7 D006579
- 650 _2
- $a peptidové fragmenty $x mozkomíšní mok $7 D010446
- 650 12
- $a glukuronidasa $x genetika $7 D005966
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a apolipoprotein E4 $x genetika $7 D053327
- 650 _2
- $a senioři nad 80 let $7 D000369
- 650 _2
- $a kognitivní dysfunkce $x mozkomíšní mok $x genetika $7 D060825
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Andel, Ross $u Memory Clinic, Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic $u Edson College of Nursing and Health Innovation, Arizona State University, Phoenix, AZ, USA
- 700 1_
- $a Jurasova, Vanesa $u Memory Clinic, Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
- 700 1_
- $a Veverova, Katerina $u Memory Clinic, Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
- 700 1_
- $a Angelucci, Francesco $u Memory Clinic, Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic $1 https://orcid.org/0000000259565925
- 700 1_
- $a Matoska, Vaclav $u Department of Clinical Biochemistry, Hematology and Immunology, Homolka Hospital, Prague, Czech Republic
- 700 1_
- $a Hort, Jakub $u Memory Clinic, Department of Neurology, Second Faculty of Medicine, Charles University and Motol University Hospital, Prague, Czech Republic
- 773 0_
- $w MED00006350 $t Journal of Alzheimer's disease $x 1875-8908 $g Roč. 105, č. 1 (2025), s. 159-171
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/40112321 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250708 $b ABA008
- 991 __
- $a 20250731091334 $b ABA008
- 999 __
- $a ok $b bmc $g 2366623 $s 1253032
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2025 $b 105 $c 1 $d 159-171 $e 20250320 $i 1875-8908 $m Journal of Alzheimer's disease $n J Alzheimers Dis $x MED00006350
- LZP __
- $a Pubmed-20250708